NCT07679581 Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4
| NCT ID | NCT07679581 |
| Status | Recruiting |
| Phase | — |
| Sponsor | L. Cinnamon Bidwell |
| Condition | Cannabis |
| Study Type | OBSERVATIONAL |
| Enrollment | 64 participants |
| Start Date | 2025-12-10 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 64 participants in total. It began in 2025-12-10 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the impact of ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on recognition memory in healthy, regular cannabis users. Participants complete the same recognition memory task after self-administering one of two different strains of cannabis flower one day and while not intoxicated another day. Event-related potentials (ERPs) are measured via electroencephalogram (EEG) during the recognition memory task. Blood is collected to quantify THC and CBD exposure. Participants also complete self-report measures of medical history, sleep quality, subjective cognitive function, physical activity, psychological functioning, substance use, and acute drug effects.
Eligibility Criteria
1. Must be between the ages of 21 and 40 and provide informed consent; 2. Must be right-handed (Laterality Quotient \> 60 on Edinburgh Handedness Inventory - Short Form136); 3. Heavy users (HU) in Experiments 1, 2, 3, and 4: 1. Must use cannabis at least 4 days during the month; 2. Must be a cannabis user for at least a year; 4. Non-users (NU) in Experiment 2: 1. Must not have used cannabis for prior 6 months; 2. Must have at least one episode of lifetime cannabis use; 5. Must self-report not using other illicit recreational drugs (e.g., cocaine, benzodiazepines (non-prescription), opiates (non-prescription), MDMA, sedatives, or methamphetamine) in the past 30 days, during the Pre-Screening; 6. Must not test positive on a urine toxicology test for drugs of abuse at the Baseline Appointment (TDS); 7. Must not be using psychotropic medications, however anti-depressant, non-benzodiazepine anti-anxiety, and ADHD medications are ok. ADHD medication users must be willing to abstain from ADHD medication use on appointment days; ADHD medications, even extended-release forms, are short acting and medication" holidays" (e.g., on weekends and holidays) are routine in individuals prescribed ADHD medications, without adverse effects. 8. Must not be a regular nicotine user (≤4 days per week; cigarette, E-cigs, or smokeless); 9. Must not have used caffeine or nicotine (cigarette, E-cigs, or smokeless) for 4 hours; 10. Must have a breath alcohol level of 0 at screening (to sign consent form); 11. Must not be actively seeking or in treatment for any substance use disorder (drug use levels will be carefully monitored via Timeline Follow Back (TLFB) throughout the study to assess any confounding influences of drug or alcohol use; 12. Female subjects must not be or trying to become pregnant (as indicated by a pregnancy test \& screening form administered at Baseline); 13. Must not be in treatment for psychotic disorder or bipolar disorder; or have a history with these disorders; 14. Must not have any physical characteristics (e.g., thick hair, head size exceeding the limit of the net, dyed hair) or experience any technical difficulties during testing that result in a poor-quality EEG recording. 15. Participants in Experiment 4 a. Must not have participated in Experiment 3
Contact & Investigator
Timothy Curran, Ph.D.
PRINCIPAL INVESTIGATOR
University of Colorado, Boulder
Frequently Asked Questions
Who can join the NCT07679581 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 40 Years, studying Cannabis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07679581 currently recruiting?
Yes, NCT07679581 is actively recruiting participants. Contact the research team at cobra.custudy@gmail.com for enrollment information.
Where is the NCT07679581 trial being conducted?
This trial is being conducted at Boulder, United States.
Who is sponsoring the NCT07679581 clinical trial?
NCT07679581 is sponsored by L. Cinnamon Bidwell. The principal investigator is Timothy Curran, Ph.D. at University of Colorado, Boulder. The trial plans to enroll 64 participants.